Cell metabolism · 2015 · Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't · PMID 25738459
Explore the library
Preclinical evidenceMitochondrial-derived 16-amino-acid peptide
MOTS-c
MOTS-c is a 16-amino-acid mitochondrial-derived peptide described in metabolic research. Endogenous peptide measurements, experimental administration and clinical treatment are different kinds of evidence.
Also indexed as: Mitochondrial-derived peptide
A clear starting point
MOTS-c is a 16-amino-acid mitochondrial-derived peptide described in metabolic research. Endogenous peptide measurements, experimental administration and clinical treatment are different kinds of evidence.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
AMPK / mitochondrial metabolism
MOTS-c is a 16-amino-acid mitochondrial-derived peptide described in metabolic research. Endogenous peptide measurements, experimental administration and clinical treatment are different kinds of evidence.
- Targets & processes
- AMPK / mitochondrial metabolism
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Metabolic stress, insulin sensitivity and skeletal-muscle signaling.
What this does not establish
The linked study shows metabolic findings in cells and mice. Human associations with naturally occurring MOTS-c are not evidence that administration improves outcomes.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
FDA reports no identified human exposure data for nominated MOTS-c drug products and possible immunogenicity and impurity concerns. Endogenous biomarker studies do not establish injection safety.
Contraindications & cautions
Not an exhaustive contraindication review. FDA reports no identified human exposure data for nominated MOTS-c drug products and possible immunogenicity and impurity concerns. Endogenous biomarker studies do not establish injection safety.
Medication & supplement interactions
Interaction information is incomplete. FDA reports no identified human exposure data for nominated MOTS-c drug products and possible immunogenicity and impurity concerns. Endogenous biomarker studies do not establish injection safety.
Regulatory status · United States
Not FDA-approved. No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
IW Interactive Learning Engine · 5 minutesMOTS-c: reading early-stage science
Explore the pathway & test your understandingYour scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.